Exclusive: OpenAI has acquired Orchestra Bio

In a strategic move, OpenAI has snapped up Orchestra Bio, a startup creating AI agents aimed at streamlining drug development for pharmaceutical firms. This acquisition signals a broader industry trend where AI companies like OpenAI and Anthropic are branching out into scientific research to diversify beyond their traditional coding and cybersecurity focus. By incorporating Orchestra's technology into its Rosalind suite, OpenAI aims to bolster its capabilities in life sciences, potentially accelerating advancements in drug discovery and development. This move underscores the growing intersection of AI and biotech, with significant implications for the future of medical research.